Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
From groundbreaking research to new collaborations at a federal level, discover the top three brain tumor news highlights and milestones for the year.
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
Meet the recipients of the ABTA’s highest honors and learn how they’re making a difference.
Meet two researchers on opposite ends of the globe dedicated to transforming the future of brain tumor treatments.
Read our top takeaways from the Society for Neuro-Oncology (SNO) Annual Meeting, the world’s largest gathering of neuro-oncology experts.
With the reigniting of the White House’s Cancer Moonshot Initiative, the ABTA recently joined the Brain Cancers Forum in Washington, D.C., to discuss opportunities in discovering treatments for brain cancers, including GBM.
After losing her husband to GBM in 2022 and receiving her own diagnosis, survivor Beth Kassab didn’t know what to expect attending the largest brain tumor conference in Chicago. Read Beth’s top takeaways:
Read three takeaways from the American Association for Cancer Research annual meeting in April.
Sangami Pugazenthi is rewarded for her research exploring biological processes behind radiation resistance in grade 2 meningiomas.
Always free for patients & caregivers
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631
Gina & Tim Abbas
Caregiver & Anaplastic Astrocytoma Survivor
800+ children & adults are diagnosed with a brain tumor every single day.
